Introduction and Objective: Diabetes self-management education and support (DSMES) improves glycemic management, yet high attrition rates limit effectiveness, particularly among Latino populations. This study used data from an ongoing pilot randomized trial to compare retention by sociodemographic factors across DSMES delivery modalities among Latino adults with type 2 diabetes (T2D). Methods: Participants (N=64) with HbA1c ≥7.5% who completed baseline and initiated intervention were included in retention analyses; participants were randomized to one of the three DSMES delivery modality: (1) text-based (n=34), (2) live telehealth (n=16), or (3) live in-person (n=14). Retention was defined as completing the intervention and 3- and 6-month assessments. A multivariable logistic regression model was fitted to predict retention, including delivery modality and sociodemographic covariates (age, education, employment) simultaneously, yielding mutually adjusted estimates. Results: Overall retention was 53% and varied by modality: text-based=65%, telehealth=44%, in-person=29%. After adjusting for sociodemographic factors, text-based DSMES demonstrated 10-fold higher retention vs telehealth (OR=0.11; 95% CI=0.02, 0.62; p=.012) and in-person delivery (OR=0.10; 95% CI=0.02, 0.55; p=.008). Employment status was the strongest predictor (OR=7.12; 95% CI=1.56, 32.56; p=.011), with unemployed/retired participants showing substantially higher retention. Age showed marginal association (OR=1.06; p=.058) while education was non-significant (p=.573). Conclusion: Text-based DSMES demonstrated higher retention than live delivery after adjusting for sociodemographic factors. Employment status strongly predicted retention, suggesting that DSMES programs using asynchronous delivery formats may better accommodate working Latino populations facing barriers to real-time participation. Disclosure E. San Diego: None. M. Ruiz: None. G.G. Ramon: None. E. Pyatak: None. M.M. Hughes: None. A.B. Nerey: None. S. Sanchez: None. S. Subramanian: None. A. Philis-Tsimikas: Research Support; Current; Dexcom, Inc., Lilly, Novo Nordisk. Advisory Panel; Current; Novo Nordisk, Gan Current; Sanofi-Aventis U.S. Funding National Institutes of Health (K01DK140528; P50MD017344); Merck (#60691)
DIEGO et al. (Fri,) studied this question.